Development of UV/HPLC methods for quantitative analysis of benznidazole in human plasma and urine for application in pediatric clinical studies

Journal of Clinical Laboratory Analysis

Volumn 27, Issue 5, 2013, Pages 384-390

  Marsón, María Elena ^a,b   Dana, Diego Dante ^b   Altcheh, Jaime ^c   García Bournissen, Facundo ^c   Mastrantonio, Guido ^a,b  

^a FACULTAD DE CIENCIAS EXACTAS   (Argentina)

^b UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^c HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

Author keywords

Benznidazole; Chagas Disease; HPLC; Plasma; Urine

Indexed keywords

BENZNIDAZOLE; ORGANIC SOLVENT;

ARTICLE; CONTROLLED STUDY; FREEZE DRYING; HUMAN; LIMIT OF QUANTITATION; LIQUID LIQUID EXTRACTION; PLASMA; QUANTITATIVE ANALYSIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; URINE;

BENZNIDAZOLE; CHAGAS DISEASE; HPLC; PLASMA; URINE;

CHAGAS DISEASE; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FREEZE DRYING; HUMANS; NITROIMIDAZOLES; SPECIMEN HANDLING; TRYPANOCIDAL AGENTS;

EID: 84884195414     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21615     Document Type: Article

References (22)

1. Barrett MP, Burchmore RJ, Stich A, et al. The trypanosomiases. Lancet 2003;362:1469-1480.
2. Moncayo A, Silveira AC. Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz 2009;104(suppl 1):17-30.
3. Schmunis GA. Epidemiology of Chagas disease in non-endemic countries: The role of international migration. Mem Inst Oswaldo Cruz 2007;102:75-85.
4. Di Girolamo C, Bodini C, Marta BL, Ciannameo A, Cacciatore F. Chagas disease at the crossroad of international migration and public health policies: Why a national screening might not be enough. Euro Surveill 2011;16:1-5.
5. Garcia-Bournissen F, Altcheh J, Della Védova CO, Giglio N, Mastrantonio G, Koren G. Pediatric clinical pharmacology studies in Chagas disease: Focus on Argentina. Paediatr Drugs 2009;11:33-37.
6. Jannin J, Villa L. An overview of Chagas disease treatment. Mem Inst Oswaldo Cruz 2007;102(Suppl 1):95-97.
7. Altcheh J, Moscatelli G, Moroni S, Garcia-Bournissen F, Freilij H. Adverse events after the use of benznidazole in infants and children with Chagas disease. Pediatrics 2011;127:212-218.
8. Raauflaub J, Ziegler WH. Single-dose pharmacokinetics of the trypanomicide benznidazole in man. Arzneim Forsch Drug Res 1979;29:1611-1614.
9. Bulffer RF, Castro JA, Fanelli SL. UV methodology for determination of antichagasic drugs Nifurtimox and Benznidazole in blood. Acta Bioquím Clín Latinoam 2011;45:463-470.
10. Workman P, White RAS, Walton MI, Owen LN, Twentyman PR. Preclinical pharmacokinetics of benznidazole. Br J Cancer 1984;50:291-303.
11. Walton MI, Workman P. Reversed-phase high performance liquid chromatographic method for the simultaneous determination of the 2-nitroimidazole benznidazole and its amine metabolite in biological fluids. J Chrom 1986;375:190-196.
12. Morilla MJ, Benavidez P, Lopez MO, Bakas L, Romero EL. Development and in vitro characterization of a benznidazole liposomal formulation. Int J Pharm 2002;249:89-99.
13. de Castro CR, Montalto de Mecca M, Fanelli SL, de Ferreyra EC, Díaz EG, Castro JA. Benznidazole-induced ultrastructural and biochemical alterations in rat esophagus. Toxicology 2003;191:189-198.
14. Guerrero L, Pinazo MJ, Posada E, Gascón J, Ribas J, Soy D. A high-performance liquid chromatographic method for benznidazole quantitation in plasma of patients with Chagas disease. Clin Chem Lab Med 2011;49:77-82.
15. Bulffer RF, Castro JA, Fanelli SL. Benznidazole levels in blood vary with age in rats. Mem Inst Oswaldo Cruz 2011;106:374-377.
16. Moreira da Silva R, Teixeira Oliveira L, Silva Barcellos NM, de Souza J, de Lana M. Preclinical monitoring of drug association in experimental chemotherapy of Chagas' disease by a new HPLC-UV method. Antimicrob Agents Chemother 2012;56(6):3344-3348.
17. La-Scalea MA, Serrano EI, Ferreira AM, Brett AM. Voltammetric behavior of benznidazole at a DNA-electrochemical biosensor. J Pharm Biom Anal 2002;29:561-568.
18. Raaflaub J. Multiple-dose kinetics of the trypanosomicide benznidazole in man. Arzneim Forsch Drug Res 1980;30:2192-2194.
19. Altcheh J, Moscatelli G, Mastrantonio G, et al. Pediatric clinical pharmacology population pharmacokinetics study of benznidazole in children with Chagas disease. Basic Clin Pharmacol Tox 2010;107(Suppl. 1):162-692.
20. Castro JA, Montalto de Mecca M, Bartel LC. Toxic side effects of drugs used to treat Chagaś disease (American trypanosomiasis). Hum Exp Tox 2006;25:471-479.
21. Viotti R, Viggliano C, Lococo B. Side effects of benznidazole treatment in chronic Chagas disease: Fears and realities. Expert Rev Anti Infect Ther 2009;7:157-163.
22. Hall BS, Wilkinson SR. Activation of benznidazole by Trypanosomal Type I Nitroreductases results in glyoxal formation. Antim Agents Chemother 2012;56:115-123.